Columbia Contrarian Core Fund
CCCRX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Columbia Funds Series Trust I MA United States of America
- IPO Date
- Sep 27, 2010
- CIK
- 0000773757
- Website
- columbiathreadneedleus.com
- Similar Companies
- Business
- Columbia Contrarian Core Fund (CCCRX) is an open-end mutual fund that seeks total return through long-term capital appreciation and current income by investing primarily in a blend of large-cap U.S. equities using a contrarian investment strategy; the fund employs a bottom-up stock selection process focusing on undervalued securities across market sectors, including technology (approximately 35%), financial services (14%), communication services (13%), healthcare (10%), and industrials (8%), with top holdings such as Microsoft Corp., NVIDIA Corp., Apple Inc., Amazon.com Inc., and Meta Platforms Inc. comprising about 31% of the portfolio; it maintains a diversified allocation with roughly 98% in U.S. stocks and 2% in cash equivalents, targeting institutional and retail investors seeking large-blend exposure. Managed by Columbia Management Investment Advisers, LLC, a subsidiary of Columbia Threadneedle Investments, with lead portfolio manager Guy Pope since 2005, the fund operates from headquarters in Boston, Massachusetts, and was originally launched on December 14, 1992, with the Class R (CCCRX) share class introduced on September 27, 2010; it serves investors primarily in the United States through various share classes including institutional, retirement, and advisor versions, with total net assets exceeding $15 billion and a net expense ratio of 1.24% for CCCRX. Recent developments include quarterly portfolio adjustments highlighted in the Q3 2025 commentary, such as exiting positions in response to earnings disappointments and guidance cuts in healthcare stocks amid elevated costs in Affordable Care Act exchanges and Medicaid markets; the fund continues to benefit from its affiliation with Columbia Threadneedle, which has pursued broader strategic enhancements in active management strategies without specific mergers, acquisitions, or name changes announced for this fund in the last 1-2 years; Morningstar reaffirmed a positive outlook on the strategy's people and process pillars despite adjustments to Medalist Ratings based on revised excess return calculations as of late 2024.